Project/Area Number |
25293366
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Emergency medicine
|
Research Institution | Nagasaki University |
Principal Investigator |
TASAKI Osamu 長崎大学, 病院(医学系), 教授 (90346221)
|
Co-Investigator(Kenkyū-buntansha) |
田島 吾郎 長崎大学, 病院(医学系), 助教 (00437427)
朝野 和典 大阪大学, 医学(系)研究科(研究院), 教授 (40202204)
嶋津 岳士 大阪大学, 医学(系)研究科(研究院), 教授 (50196474)
山野 修平 長崎大学, 病院(医学系), 助教 (60570538)
小倉 裕司 大阪大学, 医学(系)研究科(研究院), 准教授 (70301265)
廣瀬 智也 大阪大学, 医学(系)研究科(研究院), 助教 (70597509)
小島 将裕 大阪大学, 医学部附属病院, 医員 (70721091)
竹川 良介 大阪大学, 医学部附属病院, 医員 (30759577)
萩谷 英大 大阪大学, 医学部附属病院, 助教 (30718531)
松本 直也 大阪大学, 医学(系)研究科(研究院), 研究員 (50359808)
関 雅文 大阪大学, 医学部附属病院, 講師 (80432970)
濱口 重人 大阪大学, 医学部附属病院, 医員 (20735360)
入澤 太郎 大阪大学, 医学(系)研究科(研究院), 研究員 (50379202)
|
Research Collaborator |
YAMAMOTO Norihisa
|
Project Period (FY) |
2013-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2013: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
Keywords | NETs / Citrullinated Histone H3 / Sepsis / multiple Organ Failure |
Outline of Final Research Achievements |
In this study, we clarified dynamic changes of NETs in critically ill patients. First, length of NETs significantly increased on day 1 compared to day 0(the day of infection), and decreased on day 6-8 compared to day 1. In the other study, we took blood samples from intubated patients on admission to Intensive Care Unit, and determined the existence of NETs or citrullinated histon H3(Cit-H3)、which is involved in NETs formation. The existence of NETs or Cit-H3 was observed more often in patients with the presence of bacteria in tracheal aspirates. These results are suggesting that NETs are associated with infection control, and the possibility of treatment by control of NETs or Cit-H3 in patients with critically ill condition.
|